{"denoms":[{"counts":[{"groupId":"BG000","value":"1004"},{"groupId":"BG001","value":"983"},{"groupId":"BG002","value":"1987"}],"units":"Participants"}],"groups":[{"description":"Participants received capecitabine 1250 (mg/m \\^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).","id":"BG000","title":"Capecitabine"},{"description":"Participants received leucovorin 20 mg/m \\^ 2 followed by 5-fluorouracil at 425 mg/m \\^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).","id":"BG001","title":"5-Fluorouracil + Leucovorin"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"25","upperLimit":"80","value":"62.0"},{"groupId":"BG001","lowerLimit":"22","upperLimit":"82","value":"63.0"},{"groupId":"BG002","lowerLimit":"22","upperLimit":"82","value":"62.0"}]}]}],"description":"For median age, summary is based on n=1985","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"461"},{"groupId":"BG001","value":"451"},{"groupId":"BG002","value":"912"}]}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"542"},{"groupId":"BG001","value":"532"},{"groupId":"BG002","value":"1074"}]}],"title":"Male"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"}],"populationDescription":"All randomized population included all participants who were randomized to one of the two treatment arms, regardless of whether they received any study medication."}